MetaADEDB 2.0 @ LMMD
Desipramine
(XAEWZDYWZHIUCT-UHFFFAOYSA-N)
Structure
SMILES
CNCCCN1c2ccccc2CCc2c1cccc2.Cl
Molecular Formula:
C18H23ClN2
Molecular Weight:
302.842
Log P:
4.7907
Hydrogen Bond Acceptor:
1
Hydrogen Bond Donor:
2
TPSA:
15.27
CAS Number(s):
58-28-6
Synonym(s)
1.
Desipramine
2.
Desmethylimipramine
3.
Apo-Desipramine
4.
Demethylimipramine
5.
Desipramine Hydrochloride
6.
Norpramin
7.
Novo-Desipramine
8.
Nu-Desipramine
9.
PMS-Desipramine
10.
Pertofran
11.
Pertofrane
12.
Pertrofran
13.
Petylyl
14.
Ratio-Desipramine
15.
Apo Desipramine
16.
Hydrochloride, Desipramine
17.
Novo Desipramine
18.
Nu Desipramine
19.
PMS Desipramine
20.
Ratio Desipramine
External Link(s)
MeSHD003891
PubChem Compound65327
657326
24207697
ChEBI4449
CHEMBLCHEMBL1696
KEGGdr:D00812
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 6US FAERS
2AnxietyFAERS: 3US FAERS
3DizzinessFAERS: 3
Canada Vigilance: 8
Canada Vigilance
US FAERS
4TachycardiaFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
5TremorFAERS: 3
Canada Vigilance: 3
Canada Vigilance
US FAERS
6Abdominal discomfortFAERS: 2US FAERS
7Adverse eventFAERS: 2US FAERS
8CryingFAERS: 2US FAERS
9DisorientationFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
10PalpitationsFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
11ParanoiaFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
12Therapeutic response unexpected with drug substitutionFAERS: 2US FAERS
13Throat irritationFAERS: 2US FAERS
14Unevaluable eventFAERS: 2US FAERS
15Weight decreasedFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
16Abdominal PainFAERS: 1
Canada Vigilance: 3
Canada Vigilance
US FAERS
17AgitationFAERS: 1
Canada Vigilance: 2
Canada Vigilance
US FAERS
18AngerFAERS: 1US FAERS
19AphasiaFAERS: 1US FAERS
20Blood pressure immeasurableFAERS: 1US FAERS
21Burning sensationFAERS: 1US FAERS
22ConstipationFAERS: 1
Canada Vigilance: 3
Canada Vigilance
US FAERS
23Diabetes MellitusFAERS: 1US FAERS
24Diabetic KetoacidosisFAERS: 1US FAERS
25Drug DependenceFAERS: 1US FAERS
26Drug ineffective for unapproved indicationFAERS: 1US FAERS
27Drug level increasedFAERS: 1
Canada Vigilance: 2
Canada Vigilance
US FAERS
28DysgeusiaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
29Emotional disorderFAERS: 1US FAERS
30Erectile dysfunctionFAERS: 1US FAERS
31FlushingFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
32Foreign body in respiratory tractFAERS: 1US FAERS
33HeadacheFAERS: 1
Canada Vigilance: 7
Canada Vigilance
US FAERS
34HypersensitivityFAERS: 1US FAERS
35HypotensionFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
36Impaired gastric emptyingFAERS: 1US FAERS
37NauseaFAERS: 1
Canada Vigilance: 7
Canada Vigilance
US FAERS
38OverdoseFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
39Pharmaceutical product complaintFAERS: 1US FAERS
40Product substitution issueFAERS: 1US FAERS
41Product use in unapproved indicationFAERS: 1US FAERS
42PruritusFAERS: 1
Canada Vigilance: 4
Canada Vigilance
US FAERS
43Respiratory arrestFAERS: 1US FAERS
44Sinus TachycardiaFAERS: 1US FAERS
45SomnolenceFAERS: 1US FAERS
46Status EpilepticusFAERS: 1US FAERS
47Suicide attemptFAERS: 1US FAERS
48SyncopeFAERS: 1
Canada Vigilance: 2
Canada Vigilance
US FAERS
49Therapeutic response unexpectedFAERS: 1US FAERS
50ThirstFAERS: 1US FAERS
51TinnitusFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
52Toxicity to various agentsFAERS: 1US FAERS
53VertigoFAERS: 1US FAERS
54VomitingFAERS: 1US FAERS
55Wrong technique in drug usage processFAERS: 1US FAERS
56AcneCanada Vigilance: 2Canada Vigilance
57AgranulocytosisCanada Vigilance: 1Canada Vigilance
58AstheniaCanada Vigilance: 2Canada Vigilance
59AtaxiaCanada Vigilance: 1Canada Vigilance
60BilirubinuriaCanada Vigilance: 1Canada Vigilance
61Cardiac ArrestCanada Vigilance: 1Canada Vigilance
62Chest PainCanada Vigilance: 1Canada Vigilance
63ChillsCanada Vigilance: 2Canada Vigilance
64Completed SuicideCanada Vigilance: 4Canada Vigilance
65DiplopiaCanada Vigilance: 1Canada Vigilance
66DysarthriaCanada Vigilance: 1Canada Vigilance
67DyspareuniaCanada Vigilance: 1Canada Vigilance
68EosinophiliaCanada Vigilance: 1Canada Vigilance
69ErythemaCanada Vigilance: 3Canada Vigilance
70Eye painCanada Vigilance: 1Canada Vigilance
71FatigueCanada Vigilance: 2Canada Vigilance
72Feeling ColdCanada Vigilance: 2Canada Vigilance
73Head discomfortCanada Vigilance: 2Canada Vigilance
74HyperkinesiaCanada Vigilance: 1Canada Vigilance
75HypomaniaCanada Vigilance: 2Canada Vigilance
76LeukocytosisCanada Vigilance: 1Canada Vigilance
77MalaiseCanada Vigilance: 1Canada Vigilance
78Memory impairmentCanada Vigilance: 1Canada Vigilance
79Myocardial InfarctionCanada Vigilance: 2Canada Vigilance
80PallorCanada Vigilance: 1Canada Vigilance
81PetechiaeCanada Vigilance: 1Canada Vigilance
82PolyuriaCanada Vigilance: 1Canada Vigilance
83SepsisCanada Vigilance: 1Canada Vigilance
84Sexual DysfunctionCanada Vigilance: 1Canada Vigilance
85SwellingCanada Vigilance: 1Canada Vigilance
86ThrombocytopeniaCanada Vigilance: 2Canada Vigilance
87Urinary RetentionCanada Vigilance: 2Canada Vigilance
88UrticariaCanada Vigilance: 7Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.